A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists

Samy Suissa, Pierre Ernst, Jean Francois Boivin, Ralph I. Horwitz, Brian Habbick, Donald Cockroft, Lucie Blais, Mary McNutt, A (Sonia) Buist, Walter O. Spitzer

Research output: Contribution to journalArticle

254 Citations (Scopus)

Abstract

The association between the use of inhaled β-agonists and the risk of death and near-death from asthma has previously been reported. It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987. In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics. There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up. The overall rate of asthma death was 9.6 per 10,000 asthmatics per year. This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years. The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors. It also increased significantly with the use of all β-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs. Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 μg each) per month of inhaled β-agonist, the recommended limit. For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled β-agonists. We conclude that the strong association between the use of inhaled β-agonists and asthma mortality is confined primarily to the use of these drugs in excess of recommended limits. Non-asthma mortality, including that from cardiovascular causes, is not associated with the use of inhaled β-agonists.

Original languageEnglish (US)
Pages (from-to)604-610
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume149
Issue number3 I
StatePublished - Mar 1994
Externally publishedYes

Fingerprint

Cohort Studies
Asthma
Mortality
Fenoterol
Albuterol
Drug Users
Pharmaceutical Preparations
Case-Control Studies
Adrenal Cortex Hormones
Hospitalization

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Suissa, S., Ernst, P., Boivin, J. F., Horwitz, R. I., Habbick, B., Cockroft, D., ... Spitzer, W. O. (1994). A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. American Journal of Respiratory and Critical Care Medicine, 149(3 I), 604-610.

A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. / Suissa, Samy; Ernst, Pierre; Boivin, Jean Francois; Horwitz, Ralph I.; Habbick, Brian; Cockroft, Donald; Blais, Lucie; McNutt, Mary; Buist, A (Sonia); Spitzer, Walter O.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 149, No. 3 I, 03.1994, p. 604-610.

Research output: Contribution to journalArticle

Suissa, S, Ernst, P, Boivin, JF, Horwitz, RI, Habbick, B, Cockroft, D, Blais, L, McNutt, M, Buist, AS & Spitzer, WO 1994, 'A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists', American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3 I, pp. 604-610.
Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. American Journal of Respiratory and Critical Care Medicine. 1994 Mar;149(3 I):604-610.
Suissa, Samy ; Ernst, Pierre ; Boivin, Jean Francois ; Horwitz, Ralph I. ; Habbick, Brian ; Cockroft, Donald ; Blais, Lucie ; McNutt, Mary ; Buist, A (Sonia) ; Spitzer, Walter O. / A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. In: American Journal of Respiratory and Critical Care Medicine. 1994 ; Vol. 149, No. 3 I. pp. 604-610.
@article{0547395b0f064dec8290cc276d2f6ed0,
title = "A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists",
abstract = "The association between the use of inhaled β-agonists and the risk of death and near-death from asthma has previously been reported. It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987. In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics. There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up. The overall rate of asthma death was 9.6 per 10,000 asthmatics per year. This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years. The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors. It also increased significantly with the use of all β-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs. Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 μg each) per month of inhaled β-agonist, the recommended limit. For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled β-agonists. We conclude that the strong association between the use of inhaled β-agonists and asthma mortality is confined primarily to the use of these drugs in excess of recommended limits. Non-asthma mortality, including that from cardiovascular causes, is not associated with the use of inhaled β-agonists.",
author = "Samy Suissa and Pierre Ernst and Boivin, {Jean Francois} and Horwitz, {Ralph I.} and Brian Habbick and Donald Cockroft and Lucie Blais and Mary McNutt and Buist, {A (Sonia)} and Spitzer, {Walter O.}",
year = "1994",
month = "3",
language = "English (US)",
volume = "149",
pages = "604--610",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists

AU - Suissa, Samy

AU - Ernst, Pierre

AU - Boivin, Jean Francois

AU - Horwitz, Ralph I.

AU - Habbick, Brian

AU - Cockroft, Donald

AU - Blais, Lucie

AU - McNutt, Mary

AU - Buist, A (Sonia)

AU - Spitzer, Walter O.

PY - 1994/3

Y1 - 1994/3

N2 - The association between the use of inhaled β-agonists and the risk of death and near-death from asthma has previously been reported. It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987. In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics. There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up. The overall rate of asthma death was 9.6 per 10,000 asthmatics per year. This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years. The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors. It also increased significantly with the use of all β-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs. Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 μg each) per month of inhaled β-agonist, the recommended limit. For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled β-agonists. We conclude that the strong association between the use of inhaled β-agonists and asthma mortality is confined primarily to the use of these drugs in excess of recommended limits. Non-asthma mortality, including that from cardiovascular causes, is not associated with the use of inhaled β-agonists.

AB - The association between the use of inhaled β-agonists and the risk of death and near-death from asthma has previously been reported. It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987. In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics. There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up. The overall rate of asthma death was 9.6 per 10,000 asthmatics per year. This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years. The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors. It also increased significantly with the use of all β-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs. Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 μg each) per month of inhaled β-agonist, the recommended limit. For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled β-agonists. We conclude that the strong association between the use of inhaled β-agonists and asthma mortality is confined primarily to the use of these drugs in excess of recommended limits. Non-asthma mortality, including that from cardiovascular causes, is not associated with the use of inhaled β-agonists.

UR - http://www.scopus.com/inward/record.url?scp=0028214757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028214757&partnerID=8YFLogxK

M3 - Article

VL - 149

SP - 604

EP - 610

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3 I

ER -